Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma - a Nordic Lymphoma Group Trial
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Bendamustine (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms LENA-BERIT
- 21 Jul 2017 This trial has been completed in Sweden (end date: 2017-04-12).
- 11 Jul 2017 This trial has been completed in Denmark (end date: 2017-06-30).
- 27 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History